Table 1.
Direct-Acting Antiviral Drugs by Stage of Development
| Phase I | Phase II | Phase III | |
|---|---|---|---|
| NS3A/4B protease inhibitors | BMS-850032 | TMC435 | Telaprevir (VX-950) |
| ACH-1625 | BI 201335 | Boceprevir (SCH-503034) | |
| GS-9256 | Vaniprevir (MK-7009) | ||
| ABT-450 | Narlaprevir (SCH-900518) | ||
| IDX320 | Danoprevir (ITMN-191, RG7227) | ||
| GS-9451 | |||
| ACH-2684 | |||
| MK-6172 | |||
| NS5B polymerase nucleoside inhibitors | INX-184 | R7128 | |
| IDX184 | |||
| PSI-7977 | |||
| PSI-938 | |||
| NS5B polymerase non-nucleoside inhibitors | IDX375 | GS-9190 | |
| ABT-333 | Filibuvir (PF868554) | ||
| ANA-598 | |||
| NS5A inhibitors | PPI-461 | ||
| GS-5885 | |||
| BMS-824393 | |||
| Cyclophilin inhibitors | SCY-635 | ||
| Debio 025 |